R&D of New Therapies and High Prevalence of Pemphigus Vulgaris to Boost Adoption of Pemphigus Vulgaris Treatment

 

Pemphigus vulgaris is a relatively uncommon group of vulvovaginitis-like autoimmune diseases. It results in blisters on the outer skin and mucosal membranes in the body. Pemphigoid patients can also experience redness, swelling, itchiness, swelling, and peeling of the skin. Pemphigus usually affects the mouth, face, lips, throat, and genitalia. Pemphigus commonis, the most common form of pemphigus, is the least dangerous form of this disease. In this case, there is no over-the-counter medication that can cure this disease.

Pemphigus affects almost 1% of the population in the United States. The condition is caused by an exaggerated response of the immune system to infection, chemicals, or microorganisms. People who have a family history of pemphigus vulgaris are more likely to develop this condition. Symptoms typically present with fever, redness, and general malaise (fatigue). More severe cases may include polydipsia (difficulties eating), polymyalgia (pain and inflammation of the face), dyspepsia (difficulty breathing) nausea, vomiting, or abdominal pain and cramping. Pemphigus can cause complications such as oral cancer, hepatitis, and inflammation of the lung tissue. If left untreated, pemphigus vulgaris can lead to death.

Fortunately, pemphigus vulgaris treatment can be performed at home. To effectively heal blisters, treatment needs to begin shortly after the onset of symptoms. Topical anesthetics are commonly administered for this purpose, but should be avoided during wound healing because they can cause serious complications. Doctors also sometimes inject corticosteroids into inflamed areas, which has been known to cause hypothermia. The market for pemphigus vulgaris treatment is also witnessing significant R&D for major market players. For instance, in December 2020, Cabaletta Bio, Inc., a clinical-stage biotechnology company, announced that the first patient has been dosed in the DesCAARTes Phase 1 clinical trial of DSG3-CAART for the treatment of patients with mucosal-dominant pemphigus vulgaris.    

Because pemphigus vulgaris cannot be completely cured, it is important that it be treated as soon as it occurs. Patients with pemphigus usually experience long-term complications if they do not treat their condition promptly. Complications include, poor healing, fever, and erosions (or pitted openings where the blister is starting to drain). These complications can not only create discomfort for the patient, but they can also expose the patient to further complications such as infections or autoinfection. In the worst case scenario, untreated pemphigus can lead to life-threatening complications.

In order to prevent complications from occurring, doctors usually prescribe a number of medications in pemphigus vulgaris treatment. Common treatments include aminosalicylates, which prevent inflammation, steroids, and antibiotics. These medications are most effective when taken within a few days of the onset of symptoms. If the symptoms occur later in the day or night, it is generally not recommended to take these medications. A better oral health care treatment option would include taking vitamin C supplements or fish oils. Taken in high doses, these supplements and oils can greatly improve the patient's condition.